5/22/2020 | IGLM | Pfizer, Wyeth recommend rejecting tender offer made by Huguenot
|
1/2/2013 | IGLM | Wyeth redeems in full $1.5 billion of 5.5% notes due March 15, 2013
|
12/31/2009 | IG | Outlook 2010: Drug companies, money managers lead 2009's notable deals
|
11/5/2009 | IG | Moody's upgrades Wyeth
|
10/16/2009 | IG | Moody's keeps Wyeth on review
|
10/16/2009 | IG | Market Commentary: B of A bonds widen; GE Capital unmoved on earnings; industrial trading null on bank focus
|
10/16/2009 | IG | S&P lowers Pfizer, lifts Wyeth
|
10/15/2009 | IG | Moody's lowers Pfizer, keeps Wyeth on review
|
10/15/2009 | IG | Fitch cuts Pfizer, ups Wyeth
|
10/15/2009 | SS | Pfizer completes cash-and-stock acquisition of Wyeth
|
10/14/2009 | SS | Market Commentary: Pfizer to close on Wyeth acquisition; Aquiline OKs bid; Redstone keeps control of CBS, Viacom
|
9/30/2009 | SS | Market Commentary: Kraft likely to keep mum until deadline; CIT shares sink; Analyst: MSC bids nearing ceiling
|
9/25/2009 | SS | Market Commentary: Kraft's chances of Cadbury takeover viewed as high; Pfizer could take hit on Japanese deal
|
9/23/2009 | SS | Market Commentary: Cadbury move may limit investors; quick deal OK likely for Wyeth; bid sends SkyTerra shares up
|
8/17/2009 | CV | Wyeth calls $22.66 million outstanding floating-rate convertibles
|
8/4/2009 | IG | Market Commentary: FirstEnergy, Dow Chemical, Coca-Cola Enterprises, GE Capital price bonds; new deals tighten
|
7/20/2009 | SS | Wyeth shareholders agree to Pfizer merger; deal to close by year-end
|
7/20/2009 | SS | Market Commentary: China may OK Wyeth deal by fall; Addax stock sale sparks concern; Dioro, Northgate in talks
|
7/17/2009 | SS | Pfizer gets European Commission clearance for acquisition of Wyeth
|
7/17/2009 | SS | Market Commentary: China extends review of Pfizer deal; British life insurer in combo talks; CIT shares soar
|
7/15/2009 | CV | Wyeth completes put of 97.1% of floating-rate convertible debentures
|
7/1/2009 | SS | Market Commentary: Wyeth buyout expected to clear foreign reviews; Emulex, IPC get slim chances for other bids
|
6/18/2009 | SS | Market Commentary: WebMD plans merger with HLTH; Broadcom again extends tender offer; Wyeth sets vote date
|
6/17/2009 | SS | Wyeth shareholders to decide Pfizer merger at meeting on July 20
|
4/23/2009 | CV | Wyeth calls its $2 convertible preferred stock for $60.08 each; redemption date July 15
|
4/7/2009 | SS | Market Commentary: Spread widens on Wyeth stock; Biogen jumps on buyout talk; Cubist makes difficult takeover target
|
4/3/2009 | SS | Pfizer responds to FTC, says merger with Wyeth remains on track
|
3/17/2009 | SS | Market Commentary: Wyeth shares play catch-up to Pfizer bid; Exelon, NRG spar; Merck, Schering-Plough timing eyed
|
3/17/2009 | IG | Market Commentary: Pfizer sells $13.5 billion bond issue; State Street, SoCal Edison price; Pfizer bonds tighten
|
1/30/2009 | SS | Market Commentary: Genentech bid lacks support; Wyeth buyout includes hefty breakup fees; Exelon moves for NRG control
|
1/29/2009 | SS | Market Commentary: Whole Foods moves to settle with FTC; Amylin sale not expected in Icahn's wake; Wyeth shares fall
|
1/26/2009 | IG | Fitch: Wyeth on positive watch
|
1/26/2009 | IG | Market Commentary: Primary's slow pace of issuance continues; Caterpillar, Pfizer bonds weaker, McDonald's better
|
1/26/2009 | SS | Pfizer to acquire Wyeth for $68 billion
|
1/26/2009 | SS | Market Commentary: Market doubts Pfizer, Wyeth deal; Dow gets court action from Rohm & Haas; Quiksilver up on sale talk
|
1/26/2009 | CV | Market Commentary: Convertibles little changed: Wyeth steady on Pfizer deal; Amgen active ahead of earnings; AMD gains
|
1/23/2009 | CV | Market Commentary: Convertibles bounce around; selling hits Nabors, Transocean, AMD; Cubist up on earnings; Wyeth up
|
1/23/2009 | SS | Market Commentary: Interwoven bid likely all investors will get; closing concerns widen spread on American Land Lease stock
|
1/9/2009 | SS | Market Commentary: Analyst sees Elan, Pfizer combo unlikely; DOJ studies Centennial buyout; Crucell moves on deal talk
|
12/31/2008 | SP | New Issue: UBS prices $4.18 million 11.42% yield optimization notes linked to Wyeth
|
12/15/2008 | IG | Market Commentary: P&G, United Technologies, Bank of America price; John Deere to do FDIC notes; new issues tighten
|
12/1/2008 | IG | Market Commentary: Bank of America prices FDIC issue; Wisconsin Public Service taps primary; FDIC-backed notes a focus
|
11/7/2008 | CV | Market Commentary: GM, Ford weaker after reported losses, cash burn; Sprint Nextel extends gains; Wyeth firm
|
10/27/2008 | CV | Market Commentary: Convertibles mixed; Wyeth firmer; Nabors slightly better; Peabody lower, holds up better than stock
|
8/28/2008 | SP | New Issue: ABN Amro prices $0.2 million 13% reverse convertibles linked to Wyeth
|
8/8/2008 | SP | ABN Amro plans 13% knock-in notes linked to Wyeth
|
7/30/2008 | CV | Market Commentary: PSS retreats, Affiliated Managers quiet on trading start; Wyeth finds support; Penn Virginia rallies with oil
|
7/2/2008 | CV | Market Commentary: Smithfield Foods jumps to 103 on debut; GM, Ford slide; Coal names drop with stocks; Amgen adds
|
4/21/2008 | CV | Market Commentary: National City soars on financing; financials active, mixed as Bank of America reports; CIT raises $1 billion
|
3/28/2008 | SP | New Issue: Barclays prices $2 million 10% reverse convertibles linked to Wyeth
|
3/27/2008 | SP | New Issue: ABN Amro prices $2 million 10.4% reverse convertibles linked to Wyeth
|
3/25/2008 | CV | Market Commentary: Wyeth, Medtronic, Hologic trade; Bank of America lower, but Countrywide higher; MGIC prices
|
3/10/2008 | SP | Barclays to price 10% reverse convertibles linked to Wyeth
|
2/29/2008 | SP | New Issue: ABN Amro prices $0.35 million 13.25% reverse convertibles linked to Wyeth
|
2/28/2008 | SP | New Issue: Barclays prices $3 million 10.25% reverse convertibles linked to Wyeth
|
2/26/2008 | SP | New Issue: ABN Amro prices $1.6 million 13% reverse convertibles linked to Wyeth
|
2/11/2008 | IG | Fitch affirms Wyeth
|
2/11/2008 | SP | Barclays to price 10.25% reverse convertibles linked to Wyeth
|
2/7/2008 | SP | ABN Amro to price 13.25% knock-in notes linked to Wyeth
|
1/31/2008 | IG | Moody's: Wyeth view stable
|
1/30/2008 | SP | New Issue: Barclays prices $3 million 10.125% reverse convertibles linked to Wyeth
|
1/30/2008 | HY | Moody's reviews Nycomed
|
1/14/2008 | SP | SG Structured Products to price 10.2% ReConvs linked to Wyeth
|
1/10/2008 | SP | Barclays to price 10.125% reverse convertibles linked to Wyeth
|
12/19/2007 | CVIG | Moody's rates Wyeth loans A3
|
12/6/2007 | SP | UBS to price 9.5% to 11% yield optimization notes linked to Wyeth
|
11/6/2007 | SP | New Issue: Barclays prices $3 million 9.75% reverse convertibles linked to Wyeth
|
9/28/2007 | CVIG | Moody's confirms Wyeth
|
8/31/2007 | SP | New Issue: Barclays prices $1.5 million 10.5% reverse convertibles linked to Wyeth
|
8/10/2007 | CV | Market Commentary: Schering-Plough makes debut; Countrywide battered by misunderstanding; market has 'choppy' Friday
|
8/8/2007 | SP | Barclays to price 10.5% reverse convertibles linked to Wyeth
|
7/25/2007 | CV | S&P: Wyeth unaffected
|
6/21/2007 | CV | S&P ups Wyeth
|
6/11/2007 | SS | Market Commentary: Medivation spikes; H&R Block props up Jackson Hewitt, Intuit; Ford up; Affiliated Computer up
|
6/4/2007 | CV | Moody's could upgrade Wyeth
|
5/7/2007 | CV | Market Commentary: Armor climbs on BAE buyout; Yahoo! fades with merger hopes; Gold Reserve, Chemed launch deals
|
3/22/2007 | CV | S&P: Wyeth on positive watch, rates notes A
|
3/22/2007 | CV | Moody's rates Wyeth note A3
|
3/22/2007 | CV | Fitch rates Wyeth note A-
|
2/13/2007 | CV | Market Commentary: Anixter, Illumina soar on debuts; Wyeth gains on report; Waste Connections up on results; IVG prices
|
12/13/2006 | CV | Moody's upgrades Wyeth to A3
|
11/1/2006 | BTCV | Moody's may upgrade Wyeth
|
10/19/2006 | BT | Wyeth 3Q revenues up 9%, on track to reach $1 billion in annual sales
|
10/19/2006 | BT | Market Commentary: Asthmatx on deck; Ariad slides after-hours; Siga slips on PIPE; Accentia rises 42% on trial data
|
10/18/2006 | BT | Bear puts Wyeth at outperform
|
10/18/2006 | BT | Market Commentary: Trubion gets off, trips on debut; Siga skyrockets 130%; Illumina rises 19.5%; Anadys gains 10%
|
10/16/2006 | CV | Market Commentary: Open Solutions soars on buyout; Bausch and Lomb, Wyeth slip on rate fears; SanDisk gains on outlook
|
10/13/2006 | CV | Floating-rate convertibles still attractive despite peaking interest rates, says J Giordano's Berkman
|
9/29/2006 | CV | Market Commentary: Brandywine lackluster on debut; Amkor reactions mixed to revised offer; Ford gains slightly
|
9/21/2006 | BT | Wyeth at outperform by Bear Stearns
|
9/20/2006 | BT | Progenics, Wyeth test intravenous methylnaltrexone in phase 3 trial
|
8/22/2006 | BT | Wyeth, Progenics test oral methylnaltrexone in phase 2 trial
|
8/22/2006 | BT | Wyeth: FDA cancels meeting to discuss NDA for depression treatment, action letter expected in October
|
8/16/2006 | BT | Market Commentary: CV Therapeutics gains after pricing follow-on; Acadia adds again; Accentia slides
|
8/14/2006 | BT | ViroPharma, Wyeth phase 1b HCV-796 study reaches proof-of-concept milestone, triggers stock purchase
|
7/20/2006 | BT | Wyeth second-quarter net revenue up 9% to $5.2 billion, first-half 2006 net revenue up 8% at $10 billion
|
7/17/2006 | BT | Wyeth, Progenics: Methylnaltrexone receives fast-track status for treatment of postoperative ileus
|
7/17/2006 | BT | Market Commentary: Threshold plunges over 51%; Genitope firms; Vivus dives; Progenics weak; Alnylam off
|
7/12/2006 | BT | Wyeth works to resolve Guayama manufacturing facility issues
|
7/6/2006 | BT | King, Wyeth amend agreement to market, sell Altace to reduce risk of heart attack and stroke
|
6/26/2006 | BT | Wyeth Pharmaceuticals submits NDAs for menopausal, postmenopausal symptoms
|
6/26/2006 | CV | Market Commentary: Intel, Amgen under pressure; Inco rises; Chesapeake launches mandatories offering
|
6/6/2006 | BT | Wyeth, Progenics to test subcutaneous methylnalatrexone
|
6/6/2006 | BT | Wyeth phase 3 study shows temsirolimus increases survival time in patients with renal cell carcinoma
|
5/25/2006 | BT | Wyeth: study shows DVS-233 improves symptoms in adults with major depressive disorder
|
5/23/2006 | BT | Progenics reports methylnaltrexone shows benefits for opioid-induced constipation
|
5/23/2006 | BT | Wyeth says venlafaxine helps prevent depression for up to two years
|
5/22/2006 | BT | ViroPharma says HCV-795 shows promising hepatitis C antiviral activity
|
5/18/2006 | BT | Moody's lifts Wyeth view to positive
|
5/16/2006 | BT | Fitch revises Wyeth to stable from negative
|
5/11/2006 | BT | Wyeth at outperform by Bear Stearns
|
5/10/2006 | BT | Progenics maintained at neutral by Merrill
|
5/8/2006 | BT | Wyeth presents new abstracts for daily oral contraceptive Lybrel
|
5/4/2006 | BT | Wyeth at buy by Merrill
|
5/3/2006 | BTCV | S&P ups Wyeth outlook to stable
|
4/25/2006 | BT | Market Commentary: Serologicals, Millipore both up; other services names dip; DOV, Discovery dive; Neurocrine off
|
4/21/2006 | BT | Progenics, Wyeth plan to file NDA for opioid receptor antagonist
|
4/21/2006 | BT | Wyeth says EPS up slightly to $0.82 in first quarter
|
4/11/2006 | BT | Wyeth says study data shows no increased risk of breast cancer with conjugated estrogens alone
|
4/7/2006 | BT | Impax defends aNDA for generic Effexor XR in wake of Wyeth lawsuit
|
4/7/2006 | BT | Wyeth increases stake in Wyeth K.K. Japan to 80%
|
4/3/2006 | BT | Wyeth announces Scottish collaboration, invests $86 million in biomarker research
|
3/16/2006 | BT | Wyeth ends phase 3 metastatic breast cancer program with oral temsirolimus
|
3/16/2006 | BT | Wyeth at outperform by Bear Stearns
|
3/3/2006 | CV | Market Commentary: Intel holds up on hedged basis despite stock slide; Citigroup says convertible arbitrage paid off in February
|
3/2/2006 | BT | Wyeth Pharmaceuticals' antibiotic Tygacil receives 'positive opinion' in Europe
|
1/20/2006 | BT | Wyeth reiterated by Bear Stearns at outperform
|
1/13/2006 | BT | Market Commentary: Nektar up over 10% on Pfizer's move; Encysive, Alexion up big; Biopure loses 4% after follow-on
|
1/13/2006 | BT | Wyeth, Teva patent settlement over Effexor XR now in effect
|
1/13/2006 | CV | Market Commentary: Tyco moves lower on lower guidance, break-up plan; Lucent mixed; Wyeth up
|
1/12/2006 | BT | Wyeth makes equity investment in AlphaVax, expands licensing deal
|
1/3/2006 | BT | Wyeth, Trubion to collaborate on inflammatory disease, cancer drugs in deal worth up to $800 million
|
1/3/2006 | BT | Market Commentary: Adams declines; Alkermes gains; Cephalon up; Indevus off; Wyeth up, Bradley off, ViroPharma rises
|
1/3/2006 | CV | Market Commentary: Wyeth convertibles up on pact; Cephalon adds; Mercury Interactive mostly flat
|
12/23/2005 | BT | Progenics regains rights from licensees of MNTX, sells rights to Wyeth
|
12/23/2005 | BT | Market Commentary: Progenics, Wyeth rise on $416.5 million pact; Par Pharma higher; AtheroGenics gains further 7%
|
12/23/2005 | CV | Market Commentary: Albertson's trades lower in active trade; Wyeth, Omnicare gain; GM sees light buying
|
12/22/2005 | BT | Exelixis, Wyeth sign license agreement for metabolic disease compounds
|
12/22/2005 | BT | Wyeth submits NDA for desvenlafaxine extended release for depression
|
12/16/2005 | BT | Wyeth's Tygacil effective against drug-resistant bacteria, studies say
|
12/1/2005 | BT | Wyeth gets $32 million NIH development contract for HIV vaccine
|
11/21/2005 | BT | Wyeth, Neurome expand central nervous system disease research collaboration
|
11/21/2005 | BT | Wyeth extends Curis funding to continue development of Hedgehog agonist for neurological disorders
|
11/21/2005 | BT | Wyeth's Effexor XR receives FDA approval for the treatment of panic disorder
|
11/9/2005 | BTCV | Moody's rates Wyeth notes Baa1
|
11/9/2005 | BTCV | S&P rates Wyeth notes A
|
11/9/2005 | BTCV | Fitch rates Wyeth notes A-
|
10/24/2005 | BT | Market Commentary: Roche, Gilead gain on flu talks; niche flu names higher as well; Schering, Wyeth, Pfizer watched
|
10/24/2005 | BT | Bear Stearns reiterates Wyeth at market outperform
|
10/21/2005 | CV | Market Commentary: Wyeth holds up; Ford drops, but GM bonds move higher; Schlumberger off
|
10/18/2005 | BT | Teva and Wyeth settle Effexor XR litigation
|
10/10/2005 | BT | Moody's rates Wyeth's facility Baa1
|
8/23/2005 | BT | Market Commentary: Amylin stock, convertibles zoom on drug data; OSI rebounds; Merck credit finds buyers; Wyeth sold off
|
7/21/2005 | BTCV | New Issue: Goldman Sachs prices $100 million 6.25% notes mandatorily exchangeable for Wyeth
|
7/20/2005 | CV | Market Commentary: Amgen rises in mixed convertibles trading as earnings reports roil GM, Kodak, boost Wyeth
|
6/28/2005 | BT | Market Commentary: Lonza, CV Therapeutics converts on tap; Cubist zooms; Abgenix up on belt tightening; Wyeth a boost
|
6/28/2005 | CV | Market Commentary: Lonza issue emerges; Walter better as takeover anxiety eases; Interpublic holders to get windfall payment
|
4/15/2005 | CV | Market Commentary: GM, Ford selling accelerates; El Paso, Calpine, NRG plunge; Ivax, Teva lose; Lucent, Tyco unwound
|
2/8/2005 | CV | Moody's affirms Wyeth
|
1/31/2005 | CV | Fitch affirms Wyeth
|
1/14/2005 | CV | Market Commentary: CNet gains 4 points; Collegiate Pacific higher; UnumProvident up; Wyeth rises, Schering drops
|
10/13/2004 | CV | Market Commentary: Delta convertibles rise sharply; Amkor buyers heartened; Lucent edges up, Apex easier
|
9/24/2004 | CV | Market Commentary: Calpine new issue trade seen awkward; Dobson off on buy; PMA Capital exchange seen
|
9/14/2004 | CV | Market Commentary: Allied Waste issues dumped; Interpublic mandatory eyed; Mercury rises ahead of Oracle
|
6/16/2004 | CV | Market Commentary: Advanced Medical prices with wide coupon; Kellwood seen offered at 100.5; Delta plunges; JetBlue warns
|
6/9/2004 | CV | New Issue: Citigroup prices $39.8 million 6% Elks exchangeable for Wyeth
|
5/26/2004 | CV | S&P: Wyeth unaffected
|
5/25/2004 | CV | Market Commentary: Digital River, CSG deals emerge; Wild Oats at bat; Genworth edges up; Wyeth sinks; Calpine spikes
|
5/18/2004 | CV | S&P: Wyeth unaffected
|
5/18/2004 | CV | Market Commentary: Tower prices wide of revised talk, jumps to 105.5 area; TXU climbs on new plan; Wyeth off on verdict
|
4/8/2004 | CV | New Issue: Goldman Sachs $6 million 0.25% notes exchangeable for Wyeth yield 0.25%, up 22%
|
3/3/2004 | CV | S&P: Wyeth unaffected
|
2/2/2004 | CV | S&P: Wyeth unaffected by subpoena
|
1/29/2004 | CV | Market Commentary: Wyeth, Sallie Mae, Lockheed floaters see demand; hedgies hurt by premium contractions
|
1/16/2004 | CV | Market Commentary: Juniper zooms 30-plus points on positive earnings; several techs, telecoms join the party
|
12/16/2003 | CV | Market Commentary: Four deals to price after the close Tuesday; Mentor adds $125 million overnighter
|
12/12/2003 | CV | Market Commentary: A dozen new deals this week put $4.64 billion into market; all of Friday's deals higher
|
12/11/2003 | CV | Wyeth sells $850 million convertible floater at 6-mo Libor minus 50 bps, up 57.5%
|
12/11/2003 | CV | Fitch rates Wyeth converts A-
|
12/11/2003 | CV | Market Commentary: CenterPoint bid 0.125 over par in gray market; Wyeth rises to 101.875; Citizens soars on sale possibility
|
12/10/2003 | CV | S&P rates new Wyeth convertibles A
|
12/10/2003 | CV | Market Commentary: Magnum, Scottish Re, CenterPoint emerge; Emulex, Akamai decline; Wyeth bid 0.5 over par in gray
|
12/9/2003 | CV | Wyeth $850 million convertible floater talked at Libor minus 25-75 bps, up 55-60%
|
12/9/2003 | CV | Market Commentary: Another $2.575 billion of deals; Akamai, Emulex both reoffered at 98
|
7/15/2003 | CV | New Issue: Goldman Sachs prices $64.41 million 7% notes exchangeable for Wyeth
|
7/26/2002 | CV | New Issue: Goldman Sachs prices $25 million 11.5% notes mandatorily exchangeable for Wyeth
|